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Mechanisms concerning life or death decisions in protozoan parasites are still imperfectly understood. Comparison
with higher eukaryotes has led to the hypothesis that caspase-like enzymes could be involved in death pathways.
This hypothesis was reinforced by the description of caspase-related sequences in the genome of several parasites,
including Plasmodium, Trypanosoma and Leishmania. Although several teams are working to decipher the exact
role of metacaspases in protozoan parasites, partial, conflicting or negative results have been obtained with respect
to the relationship between protozoan metacaspases and cell death. The aim of this paper is to review current
knowledge of protozoan parasite metacaspases within a drug targeting perspective.
Metacaspases: a twenty-first century history
In the late nineties, Aravind from Bethesda was the first to
describe orthologues of caspases [1]. This paved the way
for Uren and colleagues to describe paracaspases from ani-
mals and slime mould, and metacaspases from plants,
fungi and protozoa, in the beginning of 21
st century [2].
Caspases are limited to metazoans, while metacaspases are
missing from them: leading to the hypothesis that meta-
caspases resemble ancestral proteases and that caspases
have diverged through evolution under environmental
stresses. Approximately a hundred papers were published
during the first decade of the new century: mostly studying
the role of metacaspase in apoptosis in the budding yeast,
Saccharomyces cerevisiae, for example [3,4]. While the
involvement of yeast metacaspase in cell death is well
documented [5,6], a non-death role for the yeast metacas-
pase Yca1p has also been described [7]. More recently,
authors have strongly expressed their disagreement with
the classification of metacaspases as part of the caspases
family [8]. It was argued that the specificity of these
enzymes should determine their classification, rather than
any similarities. Other papers with definitive titles (“Are
metacaspases caspases?” [9] and “Metacaspases are cas-
pases. Doubt no more” [10]) were published, demonstrat-
ing the vitality of the debate. Whether this controversy
will address issues of medical importance is debatable.
However, it demonstrated the requirement to explore the
role of metacaspases, as an aid to determining whether
renaming these enzymes in agreement with their definitive
specificity is needed.
Although only recently described and their function
poorly explored, metacaspases could be considered as
potential targets for new specific treatments against the
main protozoan parasites affecting humans. Elucidating
their role in physiology is certainly a requirement, but it
is clear that addressing this issue could provide new
insights into the fight against tropical diseases.
Structure/Activity of metacaspases
Peptidases are classified in the MEROPS database http://
merops.sanger.ac.uk using “clans” and “families” fea-
tures. All the sequences in the same clan are evolutiona-
rily-related, determined by similarities in protein tertiary
structures and share a similar protein fold [11]. A pepti-
dase clan consists of two letters, the first designating the
catalytic type, for example A for aspartic acid, C for
cysteine, S for serine. Because some cysteine, serine and
threonine peptidases have similar folds, the letter “P” is
used for clans of mixed catalytic type. Among the pepti-
dases forming a transient covalent bond between the
substrate and the enzyme, serine, threonine and cysteine
peptidases are well described [12].
Metacaspases (MCA) are cysteine proteases with
structural similarity to caspases and a catalytic cysteine-
histidine dyad. Caspases and metacaspases are members
of the C14 family, clan CD, with probable differences in
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any medium, provided the original work is properly cited.substrate specificity [13]. Surprisingly, it was recently
demonstrated that two different type 1 metacaspases
from a plant (Arabidopsis thaliana) differentially regu-
late superoxide-dependant cell death: AtMC1 is a pro-
death caspase-like protein while AtMC2 antagonizes this
function [14]. Metacaspases have a highly acidic S1
pocket leading to a basic specificity for arginine and
lysine at the P1 position, rather than aspartic acid speci-
ficity as seen for caspases [12,15].
Differences in substrate specificity between metacas-
pases and caspases lead to uncertainty concerning the
potential role of protozoan metacaspases in apoptosis-
like cell death, and it has been proposed that metacas-
pases and paracaspases should be separated in a specific
family in clan CD [9]. Nevertheless, it was recently
demonstrated that caspases and metacaspases can both
target the Tudor Staphylococcal Nuclease (TSN) [16].
TSN is an evolutionary conserved protein, composed of
a single Tudor domain and five staphylococcal nuclease-
like domains, and is involved in a number of transcrip-
tional and post-transcriptional pathways. Homo sapiens
TSN sequence shows a consensus cleavage site for cas-
pase-3, and proteolysis of TSN is blocked after treat-
ment with the pan-caspase inhibitor zVAD-fmk.
Although the DAVD caspase-3 cleavage motif is absent
from protozoa, fungi and plants, TSN proteins from the
plant Picea abies were found to contain several metacas-
pase cleavage sites [16]. The ability of caspase from ver-
tebrate and type 2 metacaspase from plant to cleave the
same substrate with a central role in the cell degradome
provides new evidence that metacaspase could be
involved in apoptosis control [16].
Plasmodium Metacaspases
While insecticide-treated bednets, Artemisinin-based
combined therapy (ACTs) and climatic changes have
transformed the global impact of malaria in endemic
areas, this parasitic disease remains a major life-threa-
tening challenge for millions of people. ACTs are the
drugs of choice for non-severe malaria, but parasite
resistance is speculated to appear in the near future
[17]. Thus, it is of utmost importance to decipher the
mechanisms of parasite growth control, in order to
detect new drug targets; potentially not subjected to
resistance. Apoptosis-like DNA fragmentation of Plas-
modium falciparum parasite in response to chloroquine
treatment was described more than a decade ago [18]. It
was speculated that resistance to chloroquine was
related to inhibition of apoptosis. Plasmodium berghei
features of apoptosis including condensation of chroma-
tin, DNA fragmentation and externalisation of phospha-
tidylserine were demonstrated a few years later [19].
Proteins with caspase-like activity were identified in the
cytoplasm of the ookinete, and more than 50% of the
mosquito midgut stages of the parasite die naturally by
apoptosis before gut invasion. This phenomenon was
prevented by a caspase inhibitor [19].
Metacaspase, as well as clans CA, CD and CE pro-
teases have been described in Plasmodium [20]. Clan
CA proteases are the best-characterised cysteine pro-
teases of Plasmodium (Table 1). The major functions of
clan CA proteases, including falcipains, concerned with
hemoglobin hydrolysis and erythrocyte rupture or inva-
sion was extensively reviewed a few years ago [21].
However, few studies have been conducted to decipher
the role of Plasmodium metacaspases [22,23].
Three MCAs were described in the genome of the two
major human malaria parasites, P. falciparum (PfMCA1-
3) and P. vivax (PvMCA1-3), and in the murine parasite
P. berghei (PbMCA1-3). PxMCA1 is the only enzyme
that presents the well-characterized histidine and
cysteine catalytic dyad. Patterns of expression seem to
differ between PfMCA1 and PbMCA1. PfMCA1 gene
expression was described in the erythrocytic stage
[Meslin et al, unpublished observations], PbMCA1
expression was detected in female gametocytes, in
oocysts and in sporozoites, but authors [23] failed to
demonstrate a significant level of ookinetes apoptosis
compared to other studies [19,24], and did not observe
differences between wild-type (WT) and PbMCA1-KO
ookinetes, leading to the conclusion that functional
redundancy may exist, probably through PbMCA2/3
activity. It should be kept in mind that apoptosis of nor-
mal parasites may occur in specific conditions that lead
to a message of death. A more comprehensive study of
the role of metacaspase in Plasmodium biology should
be conducted in the presence of one such message. In a
recent study, Plasmodium falciparum metacaspase
expression was measured during parasite culture in
vitro, showing a relationship with parasitemia levels and
suggesting a role in growth regulation [25]. These preli-
minary results provide some more evidence for a role of
metacaspase in Plasmodium fitness.
The expression of PfMCA1 C14 peptidase domain in
yca1 deficient S. cerevisiae led to growth retardation and a
drastic yeast cell death [Meslin et al, unpublished observa-
tions]. Interestingly, this phenotype could be blocked by
the addition of the pan caspase inhibitor z-VAD-fmk
while PfMCA1 did not exhibit a caspase-like, but an argi-
nine protease activity, as reported for other protozoan
MCAs [Meslin et al, unpublished observations]. PfMCA1
could play an initiator role leading to the activation of an
aspartate protease effector. This hypothesis is in agree-
ment with the description of PfMCA1 autoprocessing
leading to prodomain removal as typical of initiator cas-
pases [22]. PfMCA1 function could to be regulated by the
two putative binding domains described: a C2 calcium-
dependant membrane targeting domain and a CARD
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ingly, Plasmodium falciparum Tudor Staphylococcal
Nuclease was recently described and some of its interact-
ing proteins were detected using two-hybrid analysis, co-
localization and co-immunoprecipitation [26,27]. Plasmo-
dium Tudor SN exhibits RNA binding and nuclease activ-
ity. Whether Plasmodium Tudor SN could be a substrate
for metacaspase is still unknown, but it probably has a
central role in the parasite life cycle.
Trypanosomatids Metacaspases
The kinetoplastid protozoan, Trypanosoma brucei, Try-
panosoma cruzi and several Leishmania species cause,
respectively, sleeping sickness, Chagas disease and var-
ious forms of leishmaniasis [28,29]. Together, these
pathogenic agents affect millions of people across the
world, especially in developing countries, where they are
often totally mismanaged (WHO/TDR, http://www.who.
int/tdr). Metacaspases have been identified and partially
described in all trypanosomatids and with the recent dis-
covery of anti-metacaspase inhibitors, further research in
this area may prove to be clinically significant.
1 - Trypanosoma
In the African trypanosome, T. brucei, five genes encod-
ing metacaspases (TbMCA1-TbMCA5) are expressed
(Table 2). At the protein level, TbMCA2 and TbMCA3
a r eh i g h l ys i m i l a r( 8 9 %o fs e quence identity), with the
difference ascribed to putative organelle targeting-
domain at the N-terminus of TbMCA3. TbMCA5 has a
central domain, typical of a metacaspase, as well as an
additional C-terminal extension [13]. Importantly,
TbMCA1 and TbMCA4 have amino-acid substitutions
in their conserved metacaspase catalytic residues (histi-
dine to tyrosine and cysteine to serine in TbMCA1;
cysteine to serine in TbMCA4) and are therefore
expected to be enzymatically inactive [13].
Metacaspases have also been studied in their physiolo-
gical context, TbMCA2 and TbMCA3 are reportedly
expressed only in the bloodstream form of the parasite
whereas TbMCA5 is detectable throughout the parasite
life cycle, where they appear to play a role in the recy-
cling of endosomes co-localising with RAB11 in recy-
cling vesicles [30]. Further, sequential genetic deletion of
TbMCA2, TbMCA3 and TbMCA5 did not lead to cell
death and even triple knockout parasites were able to
recover growth rates comparable to wild-type cells. On
the other hand, a rapid down-regulation of their expres-
sion using RNA-interference led to a pre-cytokinesis
cell-cycle blockade; perhaps because there was ineffi-
cient time for the hypothesized compensation [13]. All
five metacaspases have been studied in the heterologous
organism S. cerevisiae,w h e r eo n l yT b M C A 4o v e r -
expression resulted in growth inhibition and cell death.
Interestingly, it was shown to be localised in the nucleus
and appeared to play a role at the mitochondrial level
by inducing a loss of respiratory competence in yeast
cells [31].
TbMCA2 has been further biochemically charac-
terised; it has arginine/lysine specificity at substrate P1
position [32] similar to plant metacaspases [9,33].
Despite the fact that it is auto-cleaved at lysine posi-
tions, this processing does not seem to be important for
its enzymatic activity. TbMCA2 also showed a strict cal-
cium dependency that could reach 1 mM for maximum
activity; a biological concentration only encountered in
acidocalcisomes. However, no experimental evidence has
yet linked TbMCA2 to these compartments [32].
So far, T. brucei metacaspases (especially TbMCA2,
TbMCA3 and TbMC5) appear to be essential in the
bloodstream form of the parasite [30] and could have
potential as clinically viable drug targets to fight sleeping
sickness.
T. cruzi expresses two metacaspase proteins, one
homologous to TbMCA2 (named TcMCA3) and a sec-
ond homologous to TbMCA5 (named TcMCA5) [34].
The TcMCA3 gene is present in 16 copies per haploid
genome and the encoded protein has been found to be
Table 1 Key features on Plasmodium metacaspases
Structure, processing and enzymatic activity Expression, localisation and function References
PbMCA1 Absence of caspase-like protease activity.
C2 domain in N-terminus.
P replaces the predicted catalytic C but a C is located
immediately adjacent.
Expressed only in female gametocytes and all
downstream mosquito stages.
Absence of loss-of-function in PbMCA1 deficient parasites.
[23]
PfMCA1 C2 and putative CARD domains in N-terminus.
Autoprocessing upstream the C14 peptidase domain.
R-specific and calcium-dependant proteolytic activity.
Absence of caspase-like protease activity.
Expressed in erythrocytic stages and mainly in the
schizont.
Induced yeast cell death and growth retardation when





Absence of the H/C catalytic dyad but a C is located one
residue upstream the consensus C for PfMCA3.
[22,23]
C2 domain: calcium-dependent membrane targeting motif. Abbreviations: BSF, bloodstream form; PCF, procyclic form; MCA, metacaspase; C, cysteine; D, aspartic
acid; H, histidine; K, lysine; N, asparagine; P, proline; R, arginine; S, serine; W, tryptophan; FHS, fresh human serum; MLS, mitochondrial localisation signal; CARD,
caspase recruitment domain.
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TcMCA5 is present as a single copy and the expressed
protein is only found in the epimastigote form of the
parasite. Attempts to biochemically characterize these
MCAs have been unsuccessful, however Kosec et al.
were able to show that TcMCAs could be involved in
the apoptosis of the parasite as they found them to relo-
calise from the cytoplasm to the nucleus during apopto-
sis induced by fresh human serum [34]. A further
caspase-like activity was reported and is most likely due
to a downstream protease.
Five studies have been conducted during the last dec-
a d et oe x p l o r et h ep r e s e n c ea n dt h er o l eo fm e t a c a s -
pases in Trypanosoma brucei and T. cruzi parasites
in vitro. While interesting information was obtained on
similarities between Trypanosoma metacaspases and cas-
pase families, proof that metacaspase activity could be
similar to caspase and involved in apoptosis-like cell
death is still lacking.
2 - Leishmania
All Leishmania species express one single metacaspase
gene except in infantum and donovani subtypes where
two metacaspases have been found encoded as GeneDB
http://www.genedb.org. Leishmania metacaspases have a
high sequence homology (77.4 to 99.8%). Structurally, they
share an N-terminal domain containing a putative mito-
chondrial-localisation signal, a central metacaspase
domain (containing the conserved catalytic dyad histidine
and cysteine) and a less conserved proline-rich C-terminal
domain (61.4 to 100% homology), which probably plays a
role in protein-protein interactions [35] (Table 3).
In L. donovani, LdMC1 and LdMC2 were reportedly
expressed in both promastigote and axenic amastigote
forms of the parasite. They exhibit an arginine/lysine-
specific activity without any requirement for proteolytic
activation, neither in normal conditions nor upon oxida-
tive stress-induced PCD. LdMCs have been found to be
localised in the acidocalcisomes where they have been
purportedly sequestered as inactive enzymes which are
released upon apoptosis induction using oxygen perox-
ide (H2O2), as measured by the increase in metacaspase
activity and TUNEL positive cells [36]. In L. major,t h e
single metacaspase (LmjMCA) was found to be able to
replace yeast metacaspase (YCA1) in the H2O2-induced
death phenotype of S. cerevisiae [35]. Although it has
similar activities towards arginine and lysine, in contrast
to LdMCs LmjMCA was reported to be activated by
autoprocessing and the purified putative catalytic
domain was 300 times more active than the non-
purified full-length LmjMCA [35].
The H2O2-induced death role of LmjMCA has been
further characterized within the parasite. LmjMCA over-
expression was found to enhance L. major sensitivity to
oxidative stress as measured by the increase of phospha-
tidylserine exposure at the parasites surface and the
rapid loss of mitochondrial membrane potential as com-
pared to wild-type parasites expressing the endogenous
metacaspase at physiological levels. LmjMCA was found
to be extensively processed and the catalytic domain
and accumulated in the cytosolic subcellular fraction
when apoptosis was induced by either H2O2,h e a ts h o c k
or anti-Leishmania drugs such as miltefosine or curcu-
min. Even though LmjMCA has a functional N-terminal
mitochondrial localisation signal, which is likely to be
responsible for the partial LmjMCA mitochondrial loca-
lisation, the central catalytic domain alone was sufficient
to enhance the parasite sensitivity to cell death indicat-
ing that the metacaspase would indirectly affect the
mitochondrion to trigger cell death [37].
Table 2 Key features on Trypanosoma metacaspases
Structure, processing and enzymatic activity Expression, localisation and function References
TbMCA1/4 S replaces the predicted catalytic C but a C is
located immediately adjacent.
Absence of peptidase activity after R/D/N/K when
TbMCA4 was expressed in S. cerevisiae or in E. coli.
TbMCA4 induced mitochondrial dysfunction, clonal death and
growth inhibition when expressed in S. cerevisiae.
Nuclear localisation for TbMCA4.
[13,31]
TbMCA2/3/5 No processing in vivo but autoprocessing for
TbMCA2 after K55 and K268 in E. coli with calcium.
Class III WW domain in N-terminus of TbMCA2/3
and in C-terminus of TbMCA5.
TbMCA2 proteolytic activity: R/K-specific, Ca
2+ dose-
dependent and processing not required.
Sensitive to leupeptin, antipain, TLCK and
component with R in P1 position but insensitive to
E64 inhibitor.
Expression in the BSF but not in the PCF for TbMCA2/3 and in
both forms for TbMCA5.
No loss-of-function phenotype detected for the triple null
mutants (Δmca2/3Δmca5).
Triple RNAi induced a rapid growth arrest and a dysregulation
of cytokinesis.
Colocalisation of TbMCA2/3/5 with RAB11-positive endosome
but no further data support involvement of TbMCAs in cell
trafficking.
[30,44]
TcMCA3/5 TcMCA3 gene is present in 16 copies and TcMCA5 in
a single copy in the T. cruzi genome.
Q/P/Y rich region in the C-terminus of TcMCA5.
Caspase-like activity concomitant with TcMCA3
nuclar relocalisation upon (FHS)-induced cell death.
Expression of TcMCA5 in epimastigote form.
Expression of TcMCA3 in the four major stages of development.
Cytoplasmic localisation and migration into the nucleus upon
FHS treatment.
Epimastogotes over-expressing TcMCA5 are more sensitive to
(FHS)-induced cell death.
[34]
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to LmjMCA when analyzed in its physiological context.
LmjMCA was found to be expressed in actively replicat-
ing amastigotes and procyclic promastigotes, but to a
lesser extent in metacyclics. It has a diffuse scattered
distribution throughout the cell in interphase, becoming
concentrated in the kinetoplast during organelle segre-
gation and relocalising to the nucleus during mitosis.
Here, it associates with the mitotic spindle, suggesting a
role during organelle segregation and cell-cycle progres-
sion. Moreover, LmjMCA null mutants were only viable
when LmjMCA was re-expressed from an episome at
physiological levels, thus reinforcing its importance in
parasite proliferation [38].
The discrepancies in metacaspase function and locali-
sation range from a single metacaspase fulfilling several
roles (as in L. major), to multiple metacaspases with
structural and functional differences (as in T. brucei).
From an evolutionary perspective, these could be of
great interest as they could be used to trace the origin
of the multiple roles fulfilled by the closely related cas-
pases in metazoans.
Targeting metacaspases to kill parasites
Caspase inhibitors are under scrutiny by several groups
working on infectious diseases in humans where apopto-
sis promotes tissue damage. Attempts were made to
understand the mechanisms involved in caspase control
in human cells, in order to control pathogen-induced
apoptosis. Caspase inhibitors have been tested in pre-
clinical studies with various models of acute or chronic
liver failure. The pan-caspase inhibitor z-VAD-fmk
decreased rat mortality after massive hepatectomy [39]
and IDN-6556 reduced ischemia-reperfusion injury in
rat [40,41]. This latter compound was used in proof-of-
concept trial with patient presenting viral hepatitis C
[42] and in human liver preservation injury trial [43].
These trials, leading to inhibit human cells apoptosis,
a r ef a rf r o mt h eg o a lt oi n d u c ep a r a s i t ea p o p t o s i sin
vivo. However, this shows that apoptosis control could
be one of the most stimulating challenges for the future.
Inhibiting human cells apoptosis to avoid tissue injury
could promote cancer if the intrinsic pathway is tar-
geted. In contrast, stimulating parasite apoptosis to
increase the anti-parasitic drug efficacy could promote
human cell destruction from a similar mechanism.
Considering the specificity of metacaspases activity in
protozoan parasites and their absence in humans, a new
research area has opened to characterize metacaspase
activators or inhibitors.
Recently, a series of inhibitors have been evaluated as
competitive inhibitors of TbMCA2 and 3, and on
T .b r u c e i ,T .c r u z i ,L .i n f a n t u mand P. falciparum para-
sites cultures in vitro [44]. Activities against these proto-
zoan parasites were in the micromolar range, far from
what would be needed, but the high selectivity for
TbMCA2 and TbMCA3, is a first interesting step.
Whether or not protozoan metacaspases are directly
involved in parasite cell death per se, it could be
speculated that their conservation in parasites present-
ing a long history of adaptation to environment implies
that metacaspases are key regulators of the parasite life
or death decision. Thus, metacaspases should be con-
sidered as potential drug target for the future. Consid-
eration of trials in progress using drugs designed
to facilitate apoptosis of cancer cells in humans leads
to speculation that similar strategies could be used to
induce protozoan death at different stages of their life
cycles.
Thus, it is of utmost importance to explore deeply the
pathways involved in parasite apoptosis, and the key
regulatory proteins that mediate cell death. In human
Table 3 Key features on Leishmania metacaspases
Structure, processing and enzymatic activity Expression, localisation and function References
LdMC1/2 P-rich region in C-terminus
No processing with or without oxidative stress (H2O2).
R/K specific proteolytic activity at pH 7.5, induced in H2O2
treated parasites.
Sensitive to leupeptin, antipain and TLCK but insensitive to
caspase inhibitors.
Absence of caspase-like protease activity.
Expressed in both promastigote and axenic amastigote
parasites.
Colocalisation with the acidocalcisome compartments.
Parasites over-expressing LdMCs are more sensitive to
(H2O2)-induced cell death.
[36]
LmjMCA P-rich region in C-terminus and signal peptide in N-
terminus (functional MLS).
Autoprocessing and R-specific proteolytic activity
dependent on the H/C catalytic dyad.
Absence of caspase-like protease activity.
LmjMCA was extensively processed and the central
catalytic domain accumulated in the cytosolic subcellular
fraction upon cell death induction.
Expressed mainly in replicating amastigotes and procyclic
promastigotes but less in metacyclic promastigotes.
Localised in the nucleus during mitosis and in kinetoplast
during organelle segregation.
Promastigotes over-expressing LmjMCA suffered from
growth retardation and dysregulations in kinetoplast
segregation, nuclear division and cytokinesis.
Δyca1 yeast over-expressing LmjMCA are more sensitive
to (H2O2)-induced cell death.
Parasites over-expressing LmjMCA showed mitochondrial
over-sensitivity to H2O2.
[35,37,38]
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steps, including through phosphorylation [45]. For
example, phosphorylation of human caspase 9 Thr125
by the cyclin-dependent kinase (CDK1) - cyclin B1 inhi-
bits caspase 9 activation. That phosphorylation is inhib-
ited by the protein kinase inhibitor staurosporine.
Additional sites of phosphorylation in caspase 9 were
also reported (Ser 196, Ser 144, Ser 183, Ser195, Tyr
153, etc.) with different effects on cell apoptosis [45]. It
could thus be speculated that parasite metacaspases
could also be regulated by phosphorylation at specific
stages of parasite cycles, and this should be taken into
account to provide definitive data on the role of meta-
caspase in parasite death and as a drug target.
Finally, the high homology among protozoan metacas-
pases and the fact that these proteins are not present in
mammals make them good candidates as drug targets to
fight parasitic diseases. A future drug should be
designed to activate the metacaspase pathway in order
to favour parasite death, either directly or through the
inhibition of one of the numerous negative controls sus-
pected to be present in fast growing parasites. Inhibition
of human cells apoptosis induced by parasitic diseases
[46] combined with induction of parasite apoptosis at
the initial steps of the infection is an integrative concept
for future treatment that still needs to be proven. In
both cases, recent breakthroughs in knowledge allow
reasonable optimism.
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